Showing results (181-190 of 335) with videos related to
Sort By:
Pageof 34
Plos One|October 17, 2012
Mir-206 regulates pulmonary artery smooth muscle cell proliferation and differentiationSamuel Jalali, Gurukumar K Ramanathan, Prasanna Tamarapu Parthasarathy, et al.Investigational New Drugs|November 9, 2012
Determinants of patient screen failures in Phase 1 clinical trialsAlexandra Mckane, Chao Sima, Ramesh K Ramanathan, et al.Vascular|April 15, 2011
A retrospective review of basilic and cephalic vein-based fistulasAnantha K Ramanathan, Nader D Nader, Maciej L Dryjski, et al.Cancer Chemotherapy and Pharmacology|May 13, 2010
A randomized phase II study of PX-12, an inhibitor of thioredoxin in patients with advanced cancer of the pancreas following progression after a gemcitabine-containing combinationRamesh K Ramanathan, James Abbruzzese, Tomislav Dragovich, et al.Cureus|December 29, 2025
A Brief Report on Outcomes of Metastatic Non-Small Cell Lung Cancer: A Retrospective Observational Study in a Community Practice SettingBrandon Poppe, Melissa S Kovacs, Neel Dharia, et al.Journal of Gastrointestinal Oncology|June 11, 2016
Dose modification and efficacy of nab-paclitaxel plus gemcitabine vs. gemcitabine for patients with metastatic pancreatic cancer: phase III MPACT trialWerner Scheithauer, Ramesh K Ramanathan, Malcolm Moore, et al.American Journal of Clinical Oncology|December 4, 2004
A Phase II trial of fixed dose rate gemcitabine in patients with advanced biliary tree carcinomaCathy Eng, Ramesh K Ramanathan, Ramesh K Ramathan, et al.Targeted Oncology|October 27, 2020
Correction to: Phase Ib Trial of the PI3K Inhibitor Copanlisib Combined with the Allosteric MEK Inhibitor Refametinib in Patients with Advanced CancerRamesh K Ramanathan, Daniel D Von Hoff, Ferry Eskens, et al.European Journal of Cancer (Oxford, England : 1990)|December 15, 2015
Development of peripheral neuropathy and its association with survival during treatment with nab-paclitaxel plus gemcitabine for patients with metastatic adenocarcinoma of the pancreas: A subset analysis from a randomised phase III trial (MPACT)David Goldstein, Daniel D Von Hoff, Malcolm Moore, et al.Investigational New Drugs|April 12, 2012
Phase I dose-escalation study to examine the safety and tolerability of LY2603618, a checkpoint 1 kinase inhibitor, administered 1 day after pemetrexed 500 mg/m(2) every 21 days in patients with cancerGlen J Weiss, Ross C Donehower, Tara Iyengar, et al.Pageof 34